Rigel Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$14.6M
Doctors Paid
7,726
Transactions
28,230
2024 Total
$1.6M
Payment Breakdown by Category
Research$7.0M (48.0%)
Consulting$3.5M (23.8%)
Food & Beverage$715,356 (4.9%)
Travel$592,764 (4.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.0M | 447 | 48.0% |
| Consulting Fee | $3.5M | 704 | 23.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.4M | 551 | 9.3% |
| Honoraria | $1.2M | 441 | 8.2% |
| Food and Beverage | $715,356 | 23,703 | 4.9% |
| Travel and Lodging | $592,764 | 2,159 | 4.1% |
| Education | $125,960 | 181 | 0.9% |
| Space rental or facility fees (teaching hospital only) | $81,400 | 39 | 0.6% |
| Grant | $31,500 | 5 | 0.2% |
Payments by Type
General
$7.6M
27,783 transactions
Research
$7.0M
447 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Study of R289 in Participants With Lower-risk Myelodysplastic Syndromes (LR MDS) | $2.8M | 0 | 95 |
| Fostamatinib (FOS) | $1.1M | 0 | 32 |
| COVID 19 | $666,623 | 0 | 21 |
| A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | $608,037 | 14 | 75 |
| C-935788-057 | $349,013 | 17 | 52 |
| C-935788-058 | $256,345 | 10 | 26 |
| C-935788-053 | $237,439 | 0 | 73 |
| A Phase II Study Evaluating Fostamatinib for Hospitalized Adults with COVID-19 | $228,928 | 0 | 1 |
| Maintenance Post Allogeneic Hematopoietic Cell Transplantation in Patients with IDH1 Mutation | $155,573 | 0 | 1 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA | $145,062 | 0 | 19 |
| Phase I/II Open-Label Study of Fostamatinib, a SYK inhibitor, in patients with Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia who have failed therapy with Hypomethylating Agents | $105,000 | 0 | 2 |
| fostamatinib in hospitalized COVID patients | $76,309 | 0 | 1 |
| Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy (FORTE) | $73,327 | 0 | 15 |
| O-FOSTA-901 | $69,722 | 0 | 22 |
| Investigator Initiated Clinical Trial Agreement: Fostamatinib in combination with ruxolitinib for treatment of patients with myelofibrosis with severe thrombocytopenia | $53,557 | 0 | 1 |
| C-935788-050 | $46,901 | 0 | 8 |
| RI935053 | $46,134 | 0 | 2 |
| Fostamatinib | $13,300 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Perry Cook, M.d, M.D | Hematology & Oncology | Brooklyn, NY | $65,537 | $0 |
| Julia King, Rn, Msn, Acnp-Bc, RN, MSN, ACNP-BC | Acute Care | Norfolk, VA | $63,099 | $0 |
| Jessica Bordelon, Aprn, APRN | Nurse Practitioner | Hammond, LA | $62,984 | $0 |
| Dr. Delong Liu, M.d., Ph.d, M.D., PH.D | Hematology | Hawthorne, NY | $62,604 | $0 |
| Dr. James Mccloskey, M.d, M.D | Hematology | Hackensack, NJ | $60,788 | $0 |
| Edward George, Md, MD | Specialist | Norfolk, VA | $60,603 | $0 |
| Dr. Khaleel Ashraf, M.d, M.D | Hematology & Oncology | Birmingham, AL | $60,072 | $0 |
| Mark Kozloff, Md, MD | Hematology & Oncology | Harvey, IL | $56,279 | $0 |
| Livia Hegerova, Md, MD | Internal Medicine | Seattle, WA | $55,410 | $0 |
| George Yaghmour | Hematology & Oncology | Los Angeles, CA | $55,303 | $0 |
| Dr. Ruchika Goel, Md, Mph, MD, MPH | Blood Banking & Transfusion Medicine | Springfield, IL | $51,880 | $0 |
| Dr. Gerald Colvin, Do, DO | Hematology & Oncology | Wakefield, RI | $51,002 | $0 |
| Kelty Baker, Md, MD | Hematology | Houston, TX | $50,931 | $0 |
| Clark Jean, Md, MD | Hematology & Oncology | Las Vegas, NV | $48,459 | $0 |
| Andrew Rettew, D.o, D.O | Hematology & Oncology | West Reading, PA | $46,900 | $0 |
| Dr. Thomas Leblanc, Md, Ma, MD, MA | Medical Oncology | Durham, NC | $45,503 | $0 |
| Mrs. Juliet Escalon, Anp, ANP | Adult Health | New York, NY | $44,801 | $0 |
| Akshay Amaraneni, Md, MD | Internal Medicine | Tucson, AZ | $42,456 | $0 |
| Dr. John Knecht, Md, MD | Medical Oncology | Webster, TX | $42,257 | $0 |
| Mr. James Dugan, Md, MD | Internal Medicine | Winston Salem, NC | $42,228 | $0 |
| Dr. Houston Holmes, M.d, M.D | Hematology & Oncology | Dallas, TX | $41,223 | $0 |
| Dr. Samuel Shelanski, Md, MD | Hematology & Oncology | Loveland, CO | $40,950 | $0 |
| Dr. John Migliano, M.d, M.D | Internal Medicine | Tucson, AZ | $40,346 | $0 |
| Christopher Nelson, Acnp-Bc, ACNP-BC | Acute Care | Aberdeen, SD | $38,796 | $0 |
| Srikanth Nagalla, Md, MD | Hematology & Oncology | Miami, FL | $36,047 | $0 |
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. has made $14.6M in payments to 7,726 healthcare providers, recorded across 28,230 transactions in the CMS Open Payments database. In 2024, the company paid $1.6M. The top product by payment volume is Tavalisse ($6.4M).
Payments were distributed across 120 medical specialties. The top specialty by payment amount is Hematology & Oncology ($3.6M to 2,307 doctors).
Payment categories include: Food & Beverage ($715,356), Consulting ($3.5M), Research ($7.0M), Travel & Lodging ($592,764).
Rigel Pharmaceuticals, Inc. is associated with 4 products in the CMS Open Payments database, including Tavalisse, Rezlidhia, and AIHA.